Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 3U54CA132384-10S1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
To create and evaluate effective COVID-19 testing uptake strategies that focus on underserved individuals who are exposed but have not accessed testing, and underserved individuals who are not routinely tested because they are unaware of their exposure or risk status in order to increase testing among these populations and reduce Covid-19 related disparities.
Communities Fighting COVID is a partnership between San Diego State's School of Public Health and numerous communities in San Diego focused on providing community-based testing to specific language-speaking communities and vulnerable populations. This partnership is funded by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics-Undeserved Populations (Radx-UP), with the aim of ensuring all Americans have access to timely COVID-19 testing and diagnosis. Many communities, particularly immigrant and people of color communities, have a harder time accessing existing COVID-19 resources due to transportation, language barriers, or other barriers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| At home testing (Aim 1) | Experimental | High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker. |
|
| Mobile testing (Aim 1) | Active Comparator | High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing. |
|
| Mobile testing approach 1 (Aim 2) | Other | Mobile testing utilizing active outreach |
|
| Mobile testing approach 2 (Aim 2) | Other | Mobile testing utilizing baseline outreach approaches |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 Testing Home-based (Aim 1) | Other | Implementation of Antigen and PCR testing at participant homes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Test uptake | Testing volume by study arm as cumulative count per hours testing site operated | Through study completion, expected to be 20 months |
| Measure | Description | Time Frame |
|---|---|---|
| Test access | Proportion of individuals by study arm who note that this strategy has facilitated ability to test. | Through study completion, expected to be 20 months |
| Test Impact (COVID-19 diagnoses) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susan M Kiene, PhD | San Diego State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Contact Households | San Diego | California | 92182 | United States |
Plan to share with Rad-X UP Coordinating Center
Shared on a periodic basis. RPPR shared with NIH on a 6-month basis
Anonymized data access
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Cluster Randomized Trial
Not provided
Not provided
Not provided
Not provided
| COVID-19 Testing Mobile (Aim 1) | Other | Implementation of Antigen and PCR testing at mobile test sites |
|
| COVID-19 Testing Mobile Approach 1 (Aim 2) | Other | Implementation of Antigen and PCR testing at mobile test sites - active outreach |
|
| COVID-19 Testing Mobile Approach 2 (Aim 2) | Other | Implementation of Antigen and PCR testing at mobile test sites - baseline outreach |
|
Proportion of COVID-19 diagnoses of those tested by study arm
| Through study completion, expected to be 20 months |
| Test Impact (number needed to screen) | Number needed to screen (number tested in order to detect one new infection). | Through study completion, expected to be 20 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |